The results of this study show that low-dose IL-2 combined with tocilizumab treatment can reduce arthritis symptoms in RA patients, promote the more stable proliferation of Tregs, and suppress the proliferation of Th2, Th17, and Th17/Treg caused by IL-2 treatment alone, suggesting its great value for patients with immune disorders mediated by high levels of Th2 and Th17. This evidence concerns the gene IL2 and immune system disorder.